Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3850 [177Lu]-oxodotreotide in the treatment of gastroenteropancreatic neuroendocrine tumors – Patient profile in the REAL LU study (pRospective obsErvationAL study to assess the effectiveness and outcomes associated with LUtathera)

Introduction: Somatostatin (SST) receptor (SSTR) radioligand therapy is an option for highly SSTR-expressing gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The REAL LU study [NCT04727723] is evaluating the effectiveness of [177Lu]-oxodotreotide (LuO) in unresectable/metastatic, progressive, SSTR-expressing, Grade (G)1 or G2 GEP-NETs in clinical practice.

Conference:

Presenting Author:

Authors: Lastoria S, Tafuto S, Rodari M, Lania A, Sansovini M,

Keywords: REAL LU, GEP-NET, RLT, neuroendocrine tumor, radioligand therapy, [177Lu]-oxodotreotide,

#972 Anti-Tumor Efficacy of Somatostatin Analogues (SSAs) in Patients with Neuroendocrine Tumors (NETs) According to Ki-67 Score: A Multicentric Study From ELIOS (Educational Learning Investigational Observational Study)

Introduction: SSAs have been demonstrated to have antiproliferative effects in ileal NETs. The 2010 WHO NET classification provides a grading score which can be helpful in predicting tumor response to SSA.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Faggiano A

Authors: Faggiano A, Carratù A, Tafuto S, Lastoria S, Von Arx C,

Keywords: NET, SSA, G1, G2, WHO classification,